Literature DB >> 6323815

Serum ceruloplasmin and copper levels in patients with primary brain tumors.

L Turecký, P Kalina, E Uhlíková, S Námerová, J Krizko.   

Abstract

Serum copper and ceruloplasmin levels are known to increase in several malignancies such as osteosarcomas, some gastrointestinal tumors, and lung cancer. In this study serum copper and ceruloplasmin levels in 40 patients with primary brain tumors were studied. Both parameters were increased in sera of patients with tumors in comparison with healthy subjects or patients with non-tumorous neurological diseases. It is concluded that copper and ceruloplasmin represent a good complement to some other nonspecific parameters in evaluating the activity of malignancy and the therapeutic results.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323815     DOI: 10.1007/bf01731643

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  [Ceruloplasmin in the serum of patients with cancer of the mammary gland (author's transl)].

Authors:  V Schreiber; T Pribyl; H Bĕlikovová
Journal:  Cas Lek Cesk       Date:  1975-07-18

2.  [Blood ceruloplasmin levels in acute lymphoblastic leukemia and Hodgkin's disease in childhood].

Authors:  M Masi; V Vecchi; F Vivarelli; P Paolucci
Journal:  Minerva Pediatr       Date:  1975-06-23       Impact factor: 1.312

3.  [Ceruloplasmin].

Authors:  V Schreiber; T Príbyl
Journal:  Cesk Fysiol       Date:  1976

4.  Biochemistry of cerebral tumours: sodium, potassium, calcium, phosphorus, magnesium, copper and sulphur contents of astrocytomata, medulloblastomata and glioblastomata multiforme.

Authors:  H M Canelas; F B De Jorge; W C Pereira; J Sallum
Journal:  J Neurochem       Date:  1968-12       Impact factor: 5.372

5.  Significance of serum copper levels in adult patients with Hodgkin's disease.

Authors:  M Hrgovcic; C F Tessmer; F B Thomas; L M Fuller; J F Gamble; C C Shullenberger
Journal:  Cancer       Date:  1973-06       Impact factor: 6.860

6.  [Cupremia and sideremia during radiotherapy of malignant lymphomas].

Authors:  L Jurga; M Wagnerová; M Klvana; P Matula
Journal:  Vnitr Lek       Date:  1978-04

7.  Hypothesis for the mechanism of elevated serum copper in cancer patients.

Authors:  G L Fisher; M Shifrine
Journal:  Oncology       Date:  1978       Impact factor: 2.935

8.  [Estimation of the copper content of astrocytomas and glioblastomas by the cuproin method (author's transl)].

Authors:  J Kaiser; F Gullotta
Journal:  Neurochirurgia (Stuttg)       Date:  1980-01

9.  The diagnostic value of serum copper levels and other hematochemical parameters in malignancies.

Authors:  G Pizzolo; T Savarin; A M Molino; A Ambrosetti; G Todeschini; L Vettore
Journal:  Tumori       Date:  1978-02-28

10.  Variations in serum copper and ceruloplasmin levels in advanced gastrointestinal cancer treated with polychemotherapy.

Authors:  A Scanni; M Tomirotti; L Licciardello; E Annibali; M Biraghi; M Trovato; M Fittipaldi; P Adamoli; G Curtarelli
Journal:  Tumori       Date:  1979-06-30
View more
  25 in total

Review 1.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.

Authors:  Mandy L Y Sin; Kathleen E Mach; Rahul Sinha; Fan Wu; Dharati R Trivedi; Emanuela Altobelli; Kristin C Jensen; Debashis Sahoo; Ying Lu; Joseph C Liao
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

Review 3.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

4.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors:  Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

5.  Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.

Authors:  Steven Brem; Stuart A Grossman; Kathryn A Carson; Pamela New; Surasak Phuphanich; Jane B Alavi; Tom Mikkelsen; Joy D Fisher
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

6.  Molecular study on copper-mediated tumor proteasome inhibition and cell death.

Authors:  Yan Xiao; D I Chen; Xia Zhang; Qiuzhi Cui; Yuhua Fan; Caifeng Bi; Q Ping Dou
Journal:  Int J Oncol       Date:  2010-07       Impact factor: 5.650

7.  Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Authors:  Ji Young Yoo; Jason Pradarelli; Amy Haseley; Jeffrey Wojton; Azeem Kaka; Anna Bratasz; Christopher A Alvarez-Breckenridge; Jun-Ge Yu; Kimerly Powell; Andrew P Mazar; Theodoros N Teknos; E Antonio Chiocca; Joseph C Glorioso; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

8.  Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.

Authors:  Raul A Barrea; Di Chen; Thomas C Irving; Q Ping Dou
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

9.  Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors.

Authors:  D Yoshida; Y Ikeda; S Nakazawa
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

10.  Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and D-penicillamine.

Authors:  D Yoshida; Y Ikeda; S Nakazawa
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.